PMV Pharmaceuticals Inc (PMVP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.32-3.99%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PMVP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PMVP — debt issuance
Dated 2026-09-01
Entry into a Material Definitive Agreement. On August 31, 2026, PMV Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of (i) (a) 22,055,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”) and in lieu of Common Stock to certain investors, (b) pre-funded warrants to purchase an agg…
Why it matters: The update can show whether cash use remains near the recent pace. It may also confirm the planned Q1 2027 NDA filing.
Watch forPMV repeats its Q1 2027 NDA plan and reports cash runway through Q2 2027 or later.
Also watch forPMV pushes the NDA beyond Q1 2027 or reports runway ending before Q2 2027.
Why it matters: The trial data will show how well rezatapopt worked in the patients planned for the NDA. Strong results could support the filing.
Supportive ifThe company reports that the ovarian cancer data meet its stated goals and support an NDA filing.
Worry ifThe company reports that the data miss its goals or no longer support an NDA filing.
Why it matters: The offering adds cash, but its warrants can add many shares. Track filings for exercises and the share count.
Worry ifSEC filings show that investors exercised warrants. The number of common shares rose above its pre-offering level.
Less concerning ifSEC filings show no warrants were exercised. Common shares outstanding did not rise from warrant exercise.
Why it matters: The company is loss-making and needs cash to run its trial and file its NDA. A shorter runway could raise the need for more funding.
Worry ifA later cash update shows runway ending before June 30, 2027.
Less concerning ifA later cash update keeps runway through June 30, 2027, or beyond.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$303 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $711 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,167 loss on $10,000 · 41.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A timely filing would keep the company's main regulatory plan on track. A delay could push back the FDA review.
Supportive ifPMV files the ovarian cancer NDA by March 31, 2027, as planned.
Worry ifPMV says the NDA will be filed after March 31, 2027, or does not file by then.